SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on July 8, 2021, covering events occurring on July 7, 2021. The registrant is a Delaware corporation with its principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Capital Events
The filing details the closing of an underwritten public offering rather than providing standard operating financial metrics such as revenue, profit, or cash flow.
- Offering Size: 2,500,000 shares of Common Stock.
- Warrants Issued: Warrants to purchase up to 125,000 shares of Common Stock.
- Warrant Exercise Price: $4.80 per share.
- Underwriter: Laidlaw & Company (UK) Ltd.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the increase in the company's share count and the issuance of new warrants following the closing of the public offering on July 7, 2021. This follows an underwriting agreement entered into on July 2, 2021.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the capital raise. The document incorporates by reference a press release dated July 7, 2021, which is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the total net proceeds received from the sale of 2,500,000 shares by reviewing the attached press release (Exhibit 99.1) or the definitive underwriting agreement.
- Confirm the dilution impact of the 2,500,000 new shares and the potential future dilution from the 125,000 warrants exercisable at $4.80.
- Check the company's updated capitalization table to reflect the post-offering share count.
- Review the use of proceeds disclosed in the press release to understand the strategic intent of the capital raise.